These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 36892723)

  • 1. De-ESCAlating RadioTherapy in breast cancer patients with pathologic complete response to neoadjuvant systemic therapy: DESCARTES study.
    van Hemert AKE; van Olmen JP; Boersma LJ; Maduro JH; Russell NS; Tol J; Engelhardt EG; Rutgers EJT; Vrancken Peeters MTFD; van Duijnhoven FH
    Breast Cancer Res Treat; 2023 May; 199(1):81-89. PubMed ID: 36892723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can axillary surgery be omitted in patients with breast pathologic complete response after neoadjuvant systemic therapy for breast cancer? A real-world retrospective study in China.
    Chen R; Li S; Li Y; Zhu Q; Shi X; Xu L; Xu Y; Zhang W; Huang X; Wang J; Zha X
    J Cancer Res Clin Oncol; 2021 Dec; 147(12):3495-3501. PubMed ID: 34398298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial.
    Kuerer HM; Smith BD; Krishnamurthy S; Yang WT; Valero V; Shen Y; Lin H; Lucci A; Boughey JC; White RL; Diego EJ; Rauch GM;
    Lancet Oncol; 2022 Dec; 23(12):1517-1524. PubMed ID: 36306810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protocol for the postoperative radiotherapy in N1 breast cancer patients (PORT-N1) trial, a prospective multicenter, randomized, controlled, non-inferiority trial of patients receiving breast-conserving surgery or mastectomy.
    Lee TH; Chang JH; Jang BS; Kim JS; Kim TH; Park W; Kim YB; Kim SS; Han W; Lee HB; Shin KH
    BMC Cancer; 2022 Nov; 22(1):1179. PubMed ID: 36384573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of pathologic complete response after single-dose MR-guided partial breast irradiation in low-risk breast cancer patients: the ABLATIVE-2 trial-a study protocol.
    Civil YA; Oei AL; Duvivier KM; Bijker N; Meijnen P; Donkers L; Verheijen S; van Kesteren Z; Palacios MA; Schijf LJ; Barbé E; Konings IRHM; -van der Houven van Oordt CWM; Westhoff PG; Meijer HJM; Diepenhorst GMP; Thijssen V; Mouliere F; Slotman BJ; van der Velde S; van den Bongard HJGD
    BMC Cancer; 2023 May; 23(1):419. PubMed ID: 37161377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Omission of Breast Surgery in Predicted Pathologic Complete Response after Neoadjuvant Systemic Therapy: A Multicenter, Single-Arm, Non-inferiority Trial.
    Jung JJ; Cheun JH; Kim SY; Koh J; Ryu JM; Yoo TK; Shin HC; Ahn SG; Park S; Lim W; Nam SE; Park MH; Kim KS; Kang T; Lee J; Youn HJ; Kim YS; Yoon CI; Kim HK; Moon HG; Han W; Cho N; Kim MK; Lee HB
    J Breast Cancer; 2024 Feb; 27(1):61-71. PubMed ID: 38433091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial.
    Boughey JC; McCall LM; Ballman KV; Mittendorf EA; Ahrendt GM; Wilke LG; Taback B; Leitch AM; Flippo-Morton T; Hunt KK
    Ann Surg; 2014 Oct; 260(4):608-14; discussion 614-6. PubMed ID: 25203877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinically node negative breast cancer patients undergoing breast conserving therapy, sentinel lymph node procedure versus follow-up: a Dutch randomized controlled multicentre trial (BOOG 2013-08).
    van Roozendaal LM; Vane MLG; van Dalen T; van der Hage JA; Strobbe LJA; Boersma LJ; Linn SC; Lobbes MBI; Poortmans PMP; Tjan-Heijnen VCG; Van de Vijver KKBT; de Vries J; Westenberg AH; Kessels AGH; de Wilt JHW; Smidt ML
    BMC Cancer; 2017 Jul; 17(1):459. PubMed ID: 28668073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of Elective Nodal Irradiation in Patients With ypN0 After Neoadjuvant Chemotherapy Followed by Breast-Conserving Surgery (KROG 16-16).
    Cho WK; Park W; Choi DH; Kim YB; Kim JH; Kim SS; Kim K; Kim JH; Ahn SJ; Lee SY; Lee J; Kim SW; Kwon J; Ahn KJ
    Clin Breast Cancer; 2019 Feb; 19(1):78-86. PubMed ID: 30241965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eliminating Breast Surgery for Invasive Cancer with Exceptional Response to Neoadjuvant Systemic Therapy: Prospective Multicenter Clinical Trial Planned Initial Feasibility Endpoint.
    Johnson HM; Valero V; Yang WT; Smith BD; Krishnamurthy S; Shen Y; Lin H; Lucci A; Rauch GM; Kuerer HM
    J Am Coll Surg; 2023 Jul; 237(1):101-108. PubMed ID: 36856291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective Avoidance of Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Human Epidermal Growth Factor 2-Positive/Triple-Negative Breast Cancer Patients With Excellent Response.
    Ryu JM; Lee H; Han W; Lee HB; Ahn SG; Kim HJ; Park HS; Choi JS; Kim H; Cho WK; Lee JE
    J Breast Cancer; 2024 Apr; 27(2):130-140. PubMed ID: 38685868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation Between Pathologic Complete Response in the Breast and Absence of Axillary Lymph Node Metastases After Neoadjuvant Systemic Therapy.
    Samiei S; van Nijnatten TJA; de Munck L; Keymeulen KBMI; Simons JM; Kooreman LFS; Siesling S; Lobbes MBI; Smidt ML
    Ann Surg; 2020 Mar; 271(3):574-580. PubMed ID: 30557203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of postmastectomy and regional nodal radiation after neoadjuvant chemotherapy for clinically lymph node-positive breast cancer: a National Cancer Database (NCDB) analysis.
    Rusthoven CG; Rabinovitch RA; Jones BL; Koshy M; Amini A; Yeh N; Jackson MW; Fisher CM
    Ann Oncol; 2016 May; 27(5):818-27. PubMed ID: 26861597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surgical Treatment After Neoadjuvant Systemic Therapy in Young Women With Breast Cancer: Results From a Prospective Cohort Study.
    Kim HJ; Dominici L; Rosenberg SM; Zheng Y; Pak LM; Poorvu PD; Ruddy KJ; Tamimi R; Schapira L; Come SE; Peppercorn J; Borges VF; Warner E; Vardeh H; Collins LC; Gaither R; King TA; Partridge AH
    Ann Surg; 2022 Jul; 276(1):173-179. PubMed ID: 33378304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast-conserving surgery after tumor downstaging by neoadjuvant chemotherapy is oncologically safe for stage III breast cancer patients.
    Shin HC; Han W; Moon HG; Im SA; Moon WK; Park IA; Park SJ; Noh DY
    Ann Surg Oncol; 2013 Aug; 20(8):2582-9. PubMed ID: 23504119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-III trial.
    Henke G; Knauer M; Ribi K; Hayoz S; Gérard MA; Ruhstaller T; Zwahlen DR; Muenst S; Ackerknecht M; Hawle H; Fitzal F; Gnant M; Mátrai Z; Ballardini B; Gyr A; Kurzeder C; Weber WP
    Trials; 2018 Dec; 19(1):667. PubMed ID: 30514362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance).
    Golshan M; Cirrincione CT; Sikov WM; Carey LA; Berry DA; Overmoyer B; Henry NL; Somlo G; Port E; Burstein HJ; Hudis C; Winer E; Ollila DW;
    Breast Cancer Res Treat; 2016 Nov; 160(2):297-304. PubMed ID: 27704226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Low Nodal Positivity Rate Among Patients With ERBB2-Positive or Triple-Negative Breast Cancer and Breast Pathologic Complete Response to Neoadjuvant Chemotherapy.
    Barron AU; Hoskin TL; Day CN; Hwang ES; Kuerer HM; Boughey JC
    JAMA Surg; 2018 Dec; 153(12):1120-1126. PubMed ID: 30193375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conservative surgery after neoadjuvant chemotherapy in patients with operable breast cancer.
    Franceschini G; Di Leone A; Natale M; Sanchez MA; Masett R
    Ann Ital Chir; 2018; 89():290. PubMed ID: 30352955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Favorable outcome with sentinel lymph node biopsy alone after neoadjuvant chemotherapy in clinically node positive breast cancer at diagnosis: Turkish Multicentric NEOSENTI-TURK MF-18-02-study.
    Cabıoğlu N; Karanlık H; Yıldırım N; Müslümanoğlu M; Çakmak Karadeniz G; Trabulus Can D; Tükenmez M; Ersoy YE; Uras C; Zengel B; Emiroğlu S; Polat AK; Yeniay L; Özkurt E; Kara H; İbiş K; Aydıner A; Özmen V; İğci A
    Eur J Surg Oncol; 2021 Oct; 47(10):2506-2514. PubMed ID: 34217580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.